An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogs

S. C. Fiocchi, K. A. Selting, M. P. Rosenberg, P. Kolli, G. Lenaz, C. Henry

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogs'. Together they form a unique fingerprint.

Medicine & Life Sciences

Agriculture & Biology